TRPA1: An asthma target with a zing
- PMID: 33625497
- PMCID: PMC7918757
- DOI: 10.1084/jem.20202507
TRPA1: An asthma target with a zing
Abstract
Asthma therapy has advanced remarkably; however, a significant number of patients respond poorly to current interventions. Balestrini et al. (2021. J. Exp. Med.https://doi.org/10.1084/jem.20201637) advance the concept that sensory nerves control inflammation in asthma, demonstrating that a novel inhibitor of TRPA1, a nerve receptor for irritants and reactive endogenous mediators, suppresses inflammation and airway smooth muscle contraction in several preclinical species.
© 2021 Jordt.
Conflict of interest statement
Disclosures: S.-E. Jordt served on the scientific advisory board of Hydra Biosciences, a company developing TRP channel inhibitors for the treatment of pain and inflammation.
Comment on
-
A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment.J Exp Med. 2021 Apr 5;218(4):e20201637. doi: 10.1084/jem.20201637. J Exp Med. 2021. PMID: 33620419 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical